According to a study reported in The Lancet Oncology and led by the University of Pennsylvania researchers, an antibody drug called pembrolizumab that are used to treat other types of cancer may also be as a treatment for malignant pleural mesothelioma (MPM), a rare, aggressive cancer that develops in the thin layer of tissue surrounding the lungs known as the pleura.
MPM is linked to exposure to asbestos fibers. MPM carries a poor prognosis, and the median survival after symptom onset is less than one year. Great efforts have been made to improve the understanding of the devastating disease. But there are still many questions in this field. Currently, effective treatment for MPM is limited.